Disarm Therapeutics
AcquiredDisarm Therapeutics is a biotech company in St. Louis, United States, founded in 2017. It has raised $30.0M across 1 round, most recently a $30.0M Series A in September 2017.
- Headquarters
- St. Louis, Missouri
- Employees
- 11–50
- Founded
- 2017
- Business Model
- B2B
- Website
- disarmtx.com
- Total Funding
- $30.0M
- Last Round
- $30.0M Series ASep 2017
- Rounds
- 1
- Acquisition Date
- Oct 2020
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
Indexed holds 1 funding round and 4 investors for this company. The full record is or through the API.
About
Disarm Therapeutics was a biotechnology company developing a new class of disease-modifying therapeutics that block SARM1 to prevent axonal degeneration, a pathological process common to many neurological diseases. Co-founded by Washington University scientists Aaron DiAntonio and Jeffrey Milbrandt, the company closed a $30 million Series A in 2017 and was acquired by Eli Lilly in October 2020, becoming a wholly-owned Lilly subsidiary focused on SARM1 inhibitor drug development.
Summary
It lists 11–50 employees. It has raised $30.0M in total across 1 round, most recently a $30.0M Series A round in Sep 2017. Investors include Eli Lilly, Atlas Venture and Lightstone Ventures.
Funding & Exit History
Oct 2020
Sign up to see all 2 events
Funding: Series A. Amounts, valuations, and investors where available.
Investors
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/disarm-therapeutics"><img src="https://indexed.vc/api/badge/company/disarm-therapeutics" alt="Disarm Therapeutics on Indexed.vc" width="260" height="76" /></a>